Right to Try laws allow Big Pharma to exploit patients' hope

“Right to Try laws allow Big Pharma to exploit patients’ hope,” Diana Zuckerman, Chicago Tribune.

If you were dying of a terminal illness and your doctor said there were no proven treatments, would you take the risk of trying an experimental, unproven drug? Many patients would say yes. But as with most medical decisions, the . . . → Read More: Right to Try laws allow Big Pharma to exploit patients’ hope

Trumping the Affordable Care Act

“On day one of the Trump Administration, we will ask Congress to immediately deliver a full repeal of Obamacare.

However, it is not enough to simply repeal this terrible legislation. We will work with Congress to make sure we have a series of reforms ready for implementation that follow free market . . . → Read More: Trumping the Affordable Care Act

Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices

“Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices,” Diana Zuckerman, The Health Care Blog.

A major proposed law that alters the way the Food and Drug Administration (FDA) approves drugs and medical devices has been wending its way through Congress since 2014. The Cures bill and Senate legislation seek . . . → Read More: Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices

The 21st Century Cures Act

In May 2015, the “21st Century Cures Act” was introduced in the U.S. House of Representatives with the goal of promoting the development and speeding the approval of new drugs and devices. Championed by the pharmaceutical, biotechnology, and device industries, some of its provisions could have a significant impact on clinical trial design, what is . . . → Read More: The 21st Century Cures Act

The full story on breast cancer screening. But do you want to listen?

“The full story on breast cancer screening. But do you want to listen?,” by Kenneth Lin, MD, MedPage Today’s KevinMD.com.

The Men Against Breast Cancer Fund and several cancer advocacy and physician organizations have posted a petition on Change.org asking Congress to place a two-year moratorium on finalizing the U.S. Preventive Services Task Force’s draft . . . → Read More: The full story on breast cancer screening. But do you want to listen?

Drug Prices Soar, Prompting Calls for Justification

“Drug Prices Soar, Prompting Calls for Justification,” by Andrew Pollack, The New York Times.

Prices for cancer drugs, some of which extend lives by only a couple of months, routinely exceed $100,000 a year, and some new ones exceed $150,000. And it is not unusual for the list prices of existing drugs to rise 10 . . . → Read More: Drug Prices Soar, Prompting Calls for Justification

How Not to Fix the F.D.A.

“How Not to Fix the F.D.A.,” by The Editorial Board, The New York Times.

A bill passed by the House and ostensibly designed to streamline the Food and Drug Administration is loaded with bad provisions and may not even be necessary. The Senate should either eliminate or rewrite the flawed . . . → Read More: How Not to Fix the F.D.A.

New Friends and Collaborators from the Lown Institute: Meet David Klemperer

Opening Reception, Lown Institute 2015

The 2015 Lown Institute Conference was a wonderful opportunity to meet people I’ve been citing or communicating with about critical issues in health care and biomedicine for some time. It was also a chance to meet new friends and potential collaborators on this road to right care.

At . . . → Read More: New Friends and Collaborators from the Lown Institute: Meet David Klemperer

Murky Devices: The PIP Breast Implant Scandal

In March 2010, French company Poly Implant Prothèse (PIP), a manufacturer of silicone breast implants since 1991 and one of the main producers of silicone breast implants for Europe and Latin America, was implicated in a scandal over a high rate of implant ruptures and use of substandard silicone. PIP had been using industrial-grade silicone . . . → Read More: Murky Devices: The PIP Breast Implant Scandal

Courageous Nonprofit Leadership Groups Greatly Needed

“Courageous Nonprofit Leadership Groups Are Greatly Needed,” Pablo Eisenberg, Chronicle of Philanthropy.

As the government has shrunk its role, the public expects more of nonprofits, but such groups can’t shoulder that burden unless they have more dollars at their disposal.

Most grant makers don’t give more than the 5 percent of assets that is the . . . → Read More: Courageous Nonprofit Leadership Groups Greatly Needed

Articles & Posts